Prescribing information for Daclatasvir Hydrochloride 60 mg tablets, including indications, dosage, safety and storage.
The Daclatasvir Hydrochloride Tablets (DAKLINZATM) are indicated for the treatment of adult chronic hepatitis C virus (HCV) infection in combination with other antiviral agents. The recommended dosage is 60 mg taken orally once daily, with or without food. The tablet is a shallow‑green, biconvex, five‑sided film‑coated tablet marked with “BMS” on one side and “215” on the other.
The leaflet provides detailed safety information, including contraindications (e.g., hypersensitivity, co‑administration with strong CYP3A4 inducers), common adverse reactions such as headache (14 %) and fatigue (11 %), and guidance for special populations (renal or hepatic impairment, elderly, pregnancy). Storage conditions, packaging details, and the manufacturer’s contact information are also included. This manual is written in Chinese.
| Strength | 60 mg per tablet |
|---|---|
| Appearance | Shallow‑green biconvex five‑sided film‑coated tablet with "BMS" and "215" markings |
| Molecular formula | C40H50N8O6·2HCl |
| Molecular weight | 738.88 (g/mol) free base, 811.80 (g/mol) hydrochloride salt |
The recommended dosage is 60 mg taken orally once daily, with or without meals.
Yes, it can be taken either before or after a meal.
If the missed dose is remembered within 20 hours, take it as soon as possible; otherwise skip it and continue with the next scheduled dose.
The most common adverse reactions are headache (≈14 %) and fatigue (≈11 %).